• Price (EUR)3.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-1.32%
  • Beta--
Data delayed at least 15 minutes, as of Feb 03 2023 19:34 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

PureTech Health plc (PureTech) is a biotherapeutics company engaged in the treatment paradigm for devastating diseases. The Company has created a pipeline through its experienced research and development team and its network of scientists, clinicians, and industry leaders. The pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both United States (U.S.) Food and Drug Administration (FDA) clearance and European marketing authorization. All of the underlying programs and platforms that resulted in the pipeline of therapeutic candidates are identified or discovered and then advanced by the PureTech team through key validation points based on insights in immunology and drug development. The Company's wholly owned pipeline consists of various programs, including LYT-100, LYT-200, LYT-210, LYT-300, LYT-500, LYT-510, and LYT-503/IMB-150.

  • Revenue in GBP (TTM)15.42m
  • Net income in GBP-11.21m
  • Incorporated2015
  • Employees95.00
  • Location
    PureTech Health PLC6 Tide Street, Suite 400BOSTON 02210United StatesUSA
  • Phone+1 (617) 482-2333
  • Fax+1 (617) 482-3337
  • Websitehttp://puretechhealth.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.